CD86 and neoplasm: Studies 36 have shown that in the tumor microenvironment, anti-CTLA-4 stimulates the activation of surrounding T cells by blocking the binding of CTLA-4 on the surface of T cells to the ligand CD80/CD86 on APCs, but does not activate T cells.